CEO, 10%
Dr. Tien-Li Lee, M.D. (age 50) is the founder, Chief Executive Officer, Secretary, and Director of Aardvark Therapeutics, Inc. (NASDAQ: AARD), a biotechnology company, since March 2017.[[1]](https://www.marketscreener.com/insider/TIEN-LI-LEE-A1V3J4/)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aard/aardvark-therapeutics/management)[[3]](https://aardvarktherapeutics.com/team/) He holds approximately 7.12% ownership in the company, valued at around $16.94M to $45M, and recently purchased 7,000 shares for $101,395 on December 11, 2025, increasing his direct ownership to 1,551,613 shares (with additional indirect holdings).[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aard/aardvark-therapeutics/management)[[4]](https://www.gurufocus.com/insider/224244/tien-li-lee)[[5]](https://www.investing.com/news/insider-trading-news/lee-tienli-ceo-of-aardvark-buys-101k-in-aard-stock-93CH-4407003)[[6]](https://longbridge.com/en/news/269582546)
Dr. Lee brings over 20 years of experience in biotechnology innovation and executive leadership, with prior roles including Chief Strategy Officer at NantKwest, Inc. (2014-2017), Director of Business Development at Simcere Pharmaceutical Group Ltd. (2011-2013), and various director positions at Scilex Pharmaceuticals, Inc. and related entities (2018-2023).[[1]](https://www.marketscreener.com/insider/TIEN-LI-LEE-A1V3J4/)[[3]](https://aardvarktherapeutics.com/team/) His expertise spans therapeutics for immunology, cardiovascular, oncology, neurology, and infectious diseases, and he is an inventor or co-inventor of multiple innovations licensed to companies including NantKwest, Simcere, Cellics Therapeutics, and Aardvark.[[3]](https://aardvarktherapeutics.com/team/) Dr. Lee holds an undergraduate degree from the University of California, Berkeley, and a doctorate from the University of California San Diego.[[1]](https://www.marketscreener.com/insider/TIEN-LI-LEE-A1V3J4/)
View full insider profile →
